Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis

Blood Cancer J. 2023 Nov 27;13(1):172. doi: 10.1038/s41408-023-00950-3.

Authors

Rajshekhar Chakraborty¹, Divaya Bhutani², Mathew S Maurer², Meera Mohan³, Suzanne Lentzsch^#², Anita D'Souza^#³

Affiliations

¹ Columbia University Irving Medical Center, New York, NY, USA. rc3360@cumc.columbia.edu.
² Columbia University Irving Medical Center, New York, NY, USA.
³ Medical College of Wisconsin, Milwaukee, WI, USA.

^# Contributed equally.

No abstract available

Publication types

Letter

MeSH terms

Amyloidosis* / drug therapy
Antibodies, Bispecific*
Antineoplastic Agents*
Humans
Immunoglobulin Light Chains
Immunoglobulin Light-chain Amyloidosis* / drug therapy

Substances

Immunoglobulin Light Chains
Antibodies, Bispecific
Antineoplastic Agents